RESUMEN
As a new oral anticoagulant, rivaroxaban is equivalent to warfarin in preventing and treating thromboembolism, but it can significantly reduce the occurrence of severe bleeding and fatal organ bleeding. This article analyzes the clinical efficacy and drug safety of rivaroxaban in the prevention and treatment of senile thromboembolic disease. The results showed that after treatment, acute thrombosis disappeared in patients with acute venous thrombosis, and no new or recurrent venous thrombosis, pulmonary embolism and death occurred. In the rivaroxaban group, 3 cases of fecal occult blood were positive at 6 months and the incidence rate was 7%. During the follow-up period, there were no significant changes in laboratory blood tests for coagulation, hemoglobin, platelet and liver and kidney function during the follow-up observation of the rivaroxaban group and between the rivaroxaban group and the warfarin group (P>0.05). Therefore, oral rivaroxaban is an effective method for the prevention and treatment of elderly patients with thromboembolic disease. Daily 10mg rivaroxaban is a safe and effective dose for the prevention and treatment of elderly patients with thrombotic diseases. The efficacy of rivaroxaban is equivalent to that of warfarin. However, the treatment is easier with better compliance and safety.